Accountants for
life sciences & biotech

R&D tax credits under the merged scheme return twenty per cent of qualifying expenditure at the standard rate, rising to twenty-seven per cent for R&D-intensive SMEs where qualifying R&D exceeds thirty per cent of total expenditure. For a typical UK life sciences startup in pre-clinical or early clinical stage, qualifying R&D routinely represents sixty to ninety per cent of total spend, and the twenty-seven per cent rate applies. Because the company is usually loss-making, the credit is received as a cash payment from HMRC rather than a corporation tax reduction, and the annual cash inflow can be the single largest line on the cash flow forecast behind the equity round itself.

The qualifying cost categories for life sciences differ meaningfully from the software-focused claims on the other industry pages. Employee costs for scientists, research associates, clinicians, and research-directed engineers qualify at full cost (salary, employer National Insurance, and pension contributions) for the time allocated to qualifying R&D projects. Contract research organisation (CRO) subcontractor costs qualify at the sixty-five per cent SME rate, and are typically the second largest line after in-house payroll for biotech running outsourced clinical or pre-clinical work. Externally provided workers (specialist researchers engaged through an intermediary) also qualify at sixty-five per cent. Clinical trial volunteer payments qualify as a specific cost category. Consumables used in experimentation qualify in full, as do specialist software licences used directly in R&D, and the running costs of laboratory equipment where the equipment is used in qualifying research.

The documentation bar for life sciences R&D claims is high, reflecting both the scale of typical claims and the scientific specificity required. Technical narratives need to identify the specific scientific uncertainty that the research is addressing, the existing state of knowledge in the field, the approaches attempted, and the advances sought. For clinical-stage work, the trial protocol, the endpoints, and the regulatory framework feed directly into the technical narrative. Cost allocation by project and by research phase is required at the level of detail that supports enquiry defence, with contemporaneous records rather than retrospective allocation. Accountants in our network preparing life sciences R&D claims work with the scientific team on the technical narrative and the CFO or founder on the cost allocation, rather than treating the claim as a tax-only exercise.

Grant funding from public and philanthropic sources is a defining feature of UK life sciences finance. Innovate UK programmes (Biomedical Catalyst, Smart Grants, SBRI), the Medical Research Council (translational research grants, industrial partnerships), the National Institute for Health and Care Research (NIHR), the Wellcome Trust, Cancer Research UK commercial partnerships, and Horizon Europe participation each fund specific research activity, and a biotech startup with a live Innovate UK collaborative R&D grant plus a Wellcome translational award plus SEIS and EIS equity is not unusual.

The accounting treatment of grant income follows FRS 102 section 24 (SORP for UK GAAP) or IAS 20 for IFRS reporters. Revenue-based grants are recognised systematically over the periods in which the related costs are incurred, which for an R&D grant funding multi-year research typically means matching the grant income to the qualifying R&D expenditure period by period. Capital-based grants (covering equipment or infrastructure) are recognised over the useful life of the asset, or netted against the asset cost depending on policy. The grant income and the related qualifying costs appear on the P&L in the same period, which preserves the net loss position and avoids artificial timing mismatches.

The interaction with the R&D claim is where accounting work matters most. Notified state aid grants (a specific category under the subsidy control rules) that subsidise qualifying R&D expenditure reduce the credit rate on the funded expenditure under the merged scheme. Non-notified subsidies may not reduce the rate depending on the specific subsidy control classification. The grant terms determine the treatment, and the subsidy classification is not always obvious from the grant offer letter. Innovate UK Collaborative R&D grants are typically notified state aid; Wellcome translational awards are typically not notified state aid; Horizon Europe participation is typically notified. A subsidy memo prepared annually maps every line of qualifying R&D expenditure to its funding source (equity-funded, notified grant, non-notified grant, or other), documents the subsidy control classification for each, and calculates the blended R&D credit rate that results. Preparing the memo at the point grants are received (rather than reconstructing retrospectively at claim time) is the control that preserves the credit rate and avoids HMRC enquiry escalation.

Cash flow modelling for a biotech startup diverges from the standard startup playbook because the spend profile is shaped by scientific and regulatory milestones rather than by commercial traction. A Series A round in biotech is typically sized to fund the company through one or two specific scientific milestones (completion of a pre-clinical programme, filing of an Investigational New Drug application, completion of Phase 1, readout of Phase 2a), with tranched release against milestone achievement. The commitments from investors cover the full round, but actual cash release is contingent on reaching the defined checkpoints, and a missed milestone typically triggers renegotiation of the subsequent tranche rather than an automatic release.

The 18-month investor cash flow model for a biotech should therefore show runway to the next milestone rather than a flat operational projection. The model needs to account for: the probability-weighted timing of milestone achievement, the probability-weighted timing of grant receipts (R&D credit cash inflow, Innovate UK quarterly drawdowns, Wellcome milestone payments), the clinical trial spend profile which is lumpy rather than even, the CRO payment terms which often include milestone-based rather than monthly billing, and the timing uncertainty around regulatory approvals including MHRA, FDA, and EMA interactions. Scenario modelling with optimistic, base case, and conservative paths on milestone timing is more material in biotech than in any other startup vertical, because a six-month slip in a clinical endpoint readout can consume an entire tranche of reserved cash and trigger a bridging round that dilutes the cap table.

The 13-week rolling cash flow model also needs biotech-specific detail. CRO invoicing terms, laboratory consumable supplier payment terms, grant drawdown timing, R&D credit receipt timing, and the timing of next-tranche release against milestone achievement all go into the forecast as discrete timed events rather than smoothed monthly flows. Accountants in our network build the milestone-linked cash flow model at first institutional round and maintain it through the life of the company, because the model is the primary control on whether the next milestone is reachable on the current runway.

When a UK biotech enters a licensing or development partnership with a pharma company, the resulting revenue stream is rarely a single flow. A typical deal structure includes an upfront payment on signing, development milestone payments (on completion of specific research or clinical stages), regulatory milestone payments (on filing or approval of an IND, NDA, or MAA), commercial milestone payments (on first commercial sale, or on sales exceeding defined thresholds), and royalties on commercial revenue. Under IFRS 15, each of these streams needs to be assessed against the contract’s performance obligations, and the transaction price allocated across them, with variable consideration estimated and constrained.

The upfront payment typically recognises over time if it represents payment for ongoing research and development activity under the licence, or at a point in time if it represents payment for a transferred licence to existing IP. Development milestones are variable consideration under IFRS 15 and are included in the transaction price only to the extent that it is highly probable no significant reversal will occur, which for early-stage milestones usually means excluding them from the transaction price until achievement is highly probable. Regulatory milestones are variable consideration with similar constraint treatment. Royalties on sales, where the licence is the dominant feature of the contract, typically recognise under the sales-based royalty exception in IFRS 15 as the underlying sales occur.

The policy work at deal signing is substantial and needs to be completed before the first financial statements that reflect the deal. An incorrect revenue recognition policy on a pharma licensing deal produces reported revenue that differs materially from what investors and acquirers will expect to see, and restating it at later investor diligence is expensive and frequently complicated by audit sign-off on the incorrect treatment. Accountants in our network work with the commercial team and the external legal counsel on the deal structure itself, not just the accounting downstream, so the terms negotiated are internally consistent with the recognition policy that will apply.

A substantial share of UK biotech startups originate as university spinouts, typically from Oxford, Cambridge, UCL, Imperial, Edinburgh, Manchester, or one of the research-intensive Russell Group institutions. The university’s technology transfer office (Oxford University Innovation, Cambridge Enterprise, UCLB, Imperial Innovations, Edinburgh Innovations) takes an equity position in the spinout in exchange for the IP licence or assignment, typically in the range of five to twenty per cent of founding equity depending on the programme and the scale of IP contribution. The founders (typically the academic inventors plus sometimes a business co-founder) take the remainder, with equity typically subject to reverse vesting over three to four years.

The cap table design at spinout incorporation affects every subsequent round, and a poorly designed opening cap table is one of the most common sources of costly rebuild at Series A. The founder shares need to be ordinary shares, issued at par, held by the individual founders directly rather than through a holding company in most cases, with clear vesting or reverse vesting provisions documented. The university equity needs to be on the same share class as founder equity in most cases, with founder consent rights and anti-dilution provisions handled through the shareholders agreement rather than the share class structure. SEIS and EIS advance assurance for the first external round requires the share structure to comply with the qualifying share rules, and some university standard-form spinout agreements include provisions (preferential rights, redemption features, conversion features) that break SEIS or EIS qualification and need to be negotiated out before advance assurance is sought.

For founder tax purposes, Business Asset Disposal Relief on eventual exit requires the five per cent ordinary share capital and voting rights threshold and the two-year holding period. Founders whose equity is diluted below five per cent over successive rounds lose BADR eligibility on the remaining stake unless specific structuring (growth shares, additional class rights) preserves the position. Planning for BADR preservation from the spinout cap table forward, rather than discovering the issue at Series B or exit, is the structural work a specialist life sciences accountant carries through.

Clinical trials introduce a set of accounting questions specific to life sciences that do not arise in other verticals. Contract research organisation (CRO) agreements for outsourced trial execution are typically the single largest line of spend during Phase 1 through Phase 3. The CRO agreement structure matters for accounting: fixed-price agreements recognise expense on a percentage-of-completion or straight-line basis depending on the deliverable pattern, while pass-through costs (trial-site payments, laboratory fees, third-party investigators) are typically recognised as incurred. CRO invoicing terms often include substantial upfront or milestone-based payments that do not align with the actual expenditure rate, which creates a timing difference between cash outflow and expense recognition that needs accrual accounting to represent accurately.

Clinical trial volunteer payments are a qualifying R&D cost under the merged scheme where the payments are specifically for participation in qualifying research. Trial-site costs including investigator fees, laboratory analysis, site monitoring, and regulatory submissions are qualifying where they relate to the research activity. Data and safety monitoring board fees, independent review board or ethics committee fees, and regulatory submission fees form part of the trial cost base. Under accrual accounting, the expense recognition needs to reflect the clinical activity undertaken in each period, not the cash payment schedule, which for long-running trials can diverge substantially.

Regulatory submission costs (IND filings with the FDA, CTA applications to the MHRA, CTA submissions to EU member state competent authorities under the Clinical Trials Regulation) are typically expensed as incurred given they do not meet the criteria for capitalisation. Post-approval costs including pharmacovigilance, post-market surveillance, and risk management plan maintenance become operating costs once a product is approved, rather than development costs. The transition from development-stage accounting to commercial-stage accounting is a material policy decision that needs to be set out clearly before the first approval.

Medical device startups face a specific regulatory cost profile that shapes the accounting. Under the UK regime, medical devices placed on the UK market require a UKCA mark (for Great Britain) with CE marking accepted under transitional arrangements, and MHRA registration for the device and the manufacturer. Devices placed on the EU market continue to require CE marking under the Medical Devices Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR), which post-Brexit typically means engaging a Notified Body located in an EU member state. Notified Body fees for MDR or IVDR conformity assessment run from tens of thousands to hundreds of thousands of pounds per device depending on risk classification, and the fees are typically payable over the assessment period.

The accounting treatment of regulatory costs follows the general principle: pre-approval regulatory costs for a specific device are typically expensed as incurred because they do not meet the criteria for capitalisation (they are not a separately identifiable intangible asset with probable future economic benefit measurable reliably at the time of expenditure, and they do not extend the useful life of an existing asset). Post-approval regulatory costs (post-market surveillance, periodic safety update reports, vigilance reporting, ongoing Notified Body surveillance fees) are operating costs of the commercial business.

For R&D credit purposes, regulatory costs that directly support qualifying research activity can qualify, including the cost of regulatory advice on trial design, the clinical evaluation report for CE or UKCA marking where the evaluation is part of the qualifying development work, and the costs of regulatory submissions for investigational use. Routine commercial regulatory costs do not qualify. Post-market surveillance costs are operating costs. For a device startup combining software and hardware (common in digital health and diagnostics), the software development costs may qualify under the standard software R&D rules, while the hardware development and regulatory costs follow the device-specific treatment. The cost allocation between the two streams, and between qualifying and non-qualifying regulatory activity, is a material claim preparation exercise.